[3] [3] ADAMS D, ANDO Y, BEIRAO JM,et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy [J]. J Neurol, 2021, 268 (6): 2109-2122.

[4] [4] ACASTER S, LO SH, NESTLER-PARR S. A survey exploring caregiver burden and health-related quality of life in hereditary transthyretin amyloidosis [J]. Orphanet J Rare Dis, 2023, 18(1): 17.

[5] [5] ADAMS D, KOIKE H, SLAMA M,et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease [J]. Nat Rev Neurol, 2019, 15(7): 387-404.

[6] [6] KEAM SJ. Inotersen: first global approval [J]. Drugs, 2018,78(13): 1371-1376.

[7] [7] BENSON MD, WADDINGTON-CRUZ M, BERK JL,et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis [J]. N Engl J Med, 2018, 379(1): 22-31.

[8] [8] ANDO Y, ADAMS D, BENSON MD,et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis [J]. Amyloid, 2022, 29 (3): 143-155.

[9] [9] BENNETT CF. Therapeutic antisense oligonucleotides are coming of age [J]. Annu Rev Med, 2019, 70: 307-321.

[10] [10] BAENZIGER JU, FIETE D. Galactose andN-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes [J]. Cell, 1980, 22 (2 Pt 2): 611-620.

[11] [11] TANOWITZ M, HETTRICK L, REVENKO A,et al. Asialoglycoprotein receptor 1 mediates productive uptake ofN-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes [J]. Nucleic Acids Res, 2017, 45 (21): 12388-12400.

[12] [12] SHEMESH CS, YU RZ, GAUS HJ,et al. Elucidation of the biotransformation pathways of a GalNAc3-conjugated antisense oligonucleotide in rats and monkeys [J]. Mol Ther Nucleic Acids, 2016, 5 (5): e319.

[13] [13] CROOKE ST, BAKER BF, XIA S,et al. Integrated assessment of the clinical performance of GalNAc3-conjugated 2'-O-methoxyethyl chimeric antisense oligonucleotides: Ⅰ. Human volunteer experience [J]. Nucleic Acid Ther, 2019, 29 (1): 16-32.

[14] [14] VINEY NJ, GUO S, TAI LJ,et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data [J]. ESC Heart Fail,2021, 8(1): 652-661.

[15] [15] PRAKASH TP, GRAHAM MJ, YU J,et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennaryN-acetylgalactosamine improves potency 10-fold in mice [J]. Nucleic Acids Res, 2014, 42(13): 8796-8807.

[16] [16] WANG Y, YU RZ, HENRY S,et al. Pharmacokinetics and clinical pharmacology considerations of GalNAc3-conjugated antisense oligonucleotides [J]. Expert Opin Drug Metab Toxicol, 2019, 15(6): 475-485.

[17] [17] FDA. Labels for NDA 217388 [EB/OL]. (2023-12-21)[2024-12-16]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217388s000lbl.pdf.

[18] [18] DIEP JK, YU RZ, VINEY NJ,et al. Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis [J]. Br J Clin Pharmacol, 2022, 88(12): 5389-5398.

[19] [19] SHEMESH CS, YU RZ, WARREN MS,et al.Assessment of the drug interaction potential of unconjugated and GalNAc3-conjugated 2'-MOE-ASOs [J]. Mol Ther Nucleic Acids, 2017,9: 34-47.

[20] [20] COELHO T, MARQUES W, JR., DASGUPTA N R,et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy [J]. J Am Med Assoc, 2023, 330(15): 1448-1458.

[21] [21] COELHO T, WADDINGTON CRUZ M, Chao CC,et al. Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen [J]. Neurol Ther, 2023, 12(1): 267-287.

[22] [22] ClinicalTrials. A study to assess the long-term safety and efficacy of eplontersen (formerly known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in patients with hereditary transthyretin-mediated amyloid polyneuropathy [EB/OL]. (2023-10-06) [2024-12-16]. https://www.clinicaltrials.gov/study/NCT05071300.

[23] [23] ClinicalTrials. CARDIO-TTRansform: a study to evaluate the efficacy and safety of eplontersen (formerly known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in participants with transthyretin-mediated amyloid cardiomyopathy (ATTR CM) [EB/OL]. (2023-08-03) [2024-12-16]. https://www.clinicaltrials.gov/study/NCT04136171.

[24] [24] ClinicalTrials. EPIC-ATTR: a study to evaluate the effect of eplontersen on the transthyretin reduction and long-term safety in Chinese subjects with transthyretin amyloid cardiomyopathy (EPIC-ATTR) [EB/OL]. (2024-01-08) [2024-12-16]. https://www.clinicaltrials.gov/study/NCT06194825.